Industry & Policy News

[UCLA] The American Association for Cancer Research has awarded Dr. Owen Witte, founding director emeritus of the UCLA Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research, with the 2024 Award for Outstanding Achievement in Blood Cancer Research.

[Natera, Inc.] Natera, Inc. announced a collaboration with the Fédération Francophone de Cancérologie Digestive and CHU Dijon Bourgogne on the CIRCULATE-PRODIGE-70 study, a prospective Phase III clinical trial in France investigating molecular residual disease guided adjuvant treatment in stage II colorectal cancer patients.

[Perspective Therapeutics] Perspective Therapeutics, Inc. announced a clinical trial collaboration agreement with Bristol Myers Squibb to evaluate the safety and tolerability of Perspective's targeted alpha-particle therapy in combination with Bristol Myers Squibb's nivolumab in patients with histologically confirmed melanoma and positive melanocortin 1 receptor imaging scans.

[KeChow Pharma (BioSpace)] KeChow Pharma announced that the China National Medical Products Administration has approved tunlametinib for the treatment of patients with NRAS mutated advanced melanoma who were previously treated with PD-1/PD-L1.

[Korea Biomedical Review] The Korea Health Industry Development Institute (KHIDI) has inked a memorandum of understanding (MOU) with the Medical Research Council, part of the UK’s Research and Innovation (UKRI).

[Genprex Inc.] Genprex, Inc. announced that the Korean Patent Office has issued a Notice of Patent Grant for a broad patent that covers the use of Genprex’s lead drug candidate, Reqorsa® Immunogene Therapy.